Literature DB >> 6136662

Ketoconazole and fungal CAPD peritonitis.

J R Chapman, D W Warnock.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6136662     DOI: 10.1016/s0140-6736(83)90534-2

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  8 in total

1.  Candida peritonitis: successful treatment with CAPD in two patients.

Authors:  M Méhes; L Mohai; G Szöllösy
Journal:  Int Urol Nephrol       Date:  1992       Impact factor: 2.370

2.  Diseases and drugs but not food decrease ketoconazole 'bioavailability'.

Authors:  T K Daneshmend
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

Review 3.  Drug therapy in patients undergoing continuous ambulatory peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  E Keller; P Reetze; P Schollmeyer
Journal:  Clin Pharmacokinet       Date:  1990-02       Impact factor: 6.447

Review 4.  Pharmacokinetics of antifungal agents in onychomycoses.

Authors:  D Debruyne; A Coquerel
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 5.  Drug therapy in patients undergoing peritoneal dialysis. Clinical pharmacokinetic considerations.

Authors:  T W Paton; W R Cornish; M A Manuel; B G Hardy
Journal:  Clin Pharmacokinet       Date:  1985 Sep-Oct       Impact factor: 6.447

Review 6.  Pharmacokinetic aspects during continuous ambulatory peritoneal dialysis: a literature review.

Authors:  R Janknegt; C H Koks
Journal:  Pharm Weekbl Sci       Date:  1984-12-14

7.  Furosemide disposition in patients on CAPD.

Authors:  U Martin; R J Winney; L F Prescott
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

Review 8.  Clinical pharmacokinetics of ketoconazole.

Authors:  T K Daneshmend; D W Warnock
Journal:  Clin Pharmacokinet       Date:  1988-01       Impact factor: 6.447

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.